Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Prosthetic Joint infections - Overview
Prosthetic Joint infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Prosthetic Joint infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Prosthetic Joint infections - Companies Involved in Therapeutics Development
Adaptive Phage Therapeutics Inc
Arietis Corp
Armata Pharmaceuticals Inc
ContraFect Corp
Integrated BioTherapeutics Inc
Lumobiotics GmbH
Osteal Therapeutics Inc
Peptilogics Inc
Pherecydes Pharma SA
Qentoros Inc
Sonoran Biosciences Inc
TenNor Therapeutics Ltd
Prosthetic Joint infections - Drug Profiles
(tobramycin + vancomycin SR) - Drug Profile
Product Description
Mechanism Of Action
A-103 - Drug Profile
Product Description
Mechanism Of Action
APSA-02 - Drug Profile
Product Description
Mechanism Of Action
BIO-PLY - Drug Profile
Product Description
Mechanism Of Action
CF-296 - Drug Profile
Product Description
Mechanism Of Action
exebacase - Drug Profile
Product Description
Mechanism Of Action
PLG-0206 - Drug Profile
Product Description
Mechanism Of Action
PP-2351 - Drug Profile
Product Description
Mechanism Of Action
Prosthetic Joint Infection (PJI) - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Activate CIPP for Prosthetic Joint Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Oncology and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
TNP-2092 - Drug Profile
Product Description
Mechanism Of Action
TPH-101 - Drug Profile
Product Description
Mechanism Of Action
Prosthetic Joint infections - Dormant Projects
Prosthetic Joint infections - Discontinued Products
Prosthetic Joint infections - Product Development Milestones
Featured News & Press Releases
Nov 29, 2022: Pherecydes Pharma announces the positive recommendation of the DSMB for the continuation of its phase II clinical study PhagoDAIR in osteoarticular infections caused by staphylococcus aureus
Nov 28, 2022: ContraFect announces ANSM approval of clinical trial application for exebacase in prosthetic joint infections
Oct 20, 2022: Peptilogics to present data at IDWeek 2022 on PLG0206, an engineered antimicrobial peptide targeting bacteria causing periprosthetic joint infection
Oct 07, 2022: Peptilogics doses first subject in periprosthetic joint infection trial
Sep 12, 2022: ContraFect announces presentation of new clinical data from a study using exebacase in the LysinDAIR procedure on patients with chronic knee prosthetic joint infection
Aug 06, 2022: Peptilogics to participate in Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting in Pittsburgh
Aug 01, 2022: Armata Pharmaceuticals announces clearance of IND for prosthetic joint infections
Jul 19, 2022: Peptilogics receives FDA fast track desigtion for PLG0206, an investigatiol peptide therapeutic in development for the treatment of periprosthetic joint infection
Apr 19, 2022: Peptilogics to present data highlighting designed antimicrobial peptide for the treatment of Periprosthetic Joint Infection (PJI) at ECCMID 2022
Mar 22, 2022: Peptilogics’ Presentations at American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting highlight peptide therapeutic PLG0206 for the treatment of periprosthetic joint infection (PJI)
Jan 10, 2022: Peptilogics announces FDA clearance of investigatiol new drug application to initiate clinical trial of PLG0206 in periprosthetic joint infection
Dec 01, 2021: Peptilogics announces two peer-reviewed publications on designed peptide therapeutic PLG0206 for periprosthetic joint infection
Sep 29, 2021: Peptilogics presents positive first-in-human phase 1 data for its lead engineered antibacterial peptide, PLG0206, at IDWeek 2021
Sep 22, 2021: Peptilogics to present first-in-human phase 1 clinical data of PLG0206 at IDWeek 2021
May 26, 2021: ContraFect announces multiple publications on exebacase, including first manuscript on local administration of lysin for potential treatment of prosthetic joint infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Prosthetic Joint infections, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Prosthetic Joint infections, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Prosthetic Joint infections - Pipeline by Adaptive Phage Therapeutics Inc, 2022
Prosthetic Joint infections - Pipeline by Arietis Corp, 2022
Prosthetic Joint infections - Pipeline by Armata Pharmaceuticals Inc, 2022
Prosthetic Joint infections - Pipeline by ContraFect Corp, 2022
Prosthetic Joint infections - Pipeline by Integrated BioTherapeutics Inc, 2022
Prosthetic Joint infections - Pipeline by Lumobiotics GmbH, 2022
Prosthetic Joint infections - Pipeline by Osteal Therapeutics Inc, 2022
Prosthetic Joint infections - Pipeline by Peptilogics Inc, 2022
Prosthetic Joint infections - Pipeline by Pherecydes Pharma SA, 2022
Prosthetic Joint infections - Pipeline by Qentoros Inc, 2022
Prosthetic Joint infections - Pipeline by Sonoran Biosciences Inc, 2022
Prosthetic Joint infections - Pipeline by TenNor Therapeutics Ltd, 2022
Prosthetic Joint infections - Dormant Projects, 2022
Prosthetic Joint infections - Discontinued Products, 2022